Hypercholesterolemia drugs market forecast 

Extensive research carried out by the analysts at Technavio has shown that the global hypercholesterolemia drugs market is expected to reach more than USD 13 billion by 2020. Elevated levels of cholesterol in the blood lead to its deposition in the arterial walls, eventually leading to atherosclerosis. This results in the narrowing of blood vessels, decreasing blood flow to the heart muscles that might induce a heart attack.

High cholesterol levels constitute for nearly one-third of the ischemic heart disease and stroke in developing nations like India and China. According to WHO, in men aged above 40 years, a 10% decrease in serum cholesterol level reduces the risk of heart disease by almost 50% within five years. Therefore, as per the cardiovascular risk management guidelines, it is imperative to reduce the blood cholesterol level to significantly lower the risk of cardiovascular diseases.

Hypercholesterolemia drugs market drivers

In the market research study, the analysts have estimated factors the increasing use of combination therapies to contribute to the growth of this market in the coming years. Combination drugs are mostly used for managing lipid abnormalities. Combination drugs have advantages over monotherapies both in terms of efficacy and reduced incidences of adverse effects. Also, combination drugs are priced lower, have simpler logistics distribution, and show improved patient compliance than monotherapy.

Hypercholesterolemia drugs market segmentation by drug class 

• Statins
• Non-statins

During 2015, statins dominated the market and accounted for more than 80% of the market share in terms of revenue. Statins are structural analogs of the HMG-CoA enzyme and block HMG-CoA reductase enzyme activity, which catalyzes the rate-limiting step in de novo cholesterol synthesis. By lowering the blood cholesterol levels, statins bring down the danger of chest pain, heart attack, and stroke caused by a blocked blood vessel.

Hypercholesterolemia drugs market worth based on geography

• Americas
• APAC
• EMEA

The Americas dominated the global hypercholesterolemia drugs market and accounted for more than 56% of the market share in terms of revenue. This market is expected to witness declining growth, owing to competition from the generic versions of branded drugs. For instance, Crestor by AstraZeneca is set to expire in the US in 2016 while Lipitor's patent expired in 2011. However, the market is expected to recover due to an increase in the patient pool.

Hypercholesterolemia drugs industry size as per key vendors

The global hypercholesterolemia drugs market is highly competitive due to the presence of well-established global and regional providers. New players are also entering the market as they have huge growth opportunities. Also, large vendors are engaged in strategic alliances to market and manufacture drugs.

The leading vendors in the hypercholesterolemia drugs market

• AstraZeneca
• Merck
• Pfizer
• Aegerion Pharmaceuticals
• AbbVie
• Sanofi

Key questions answered in the report include

• What will the hypercholesterolemia drugs market size and the growth rate be in 2020?
• What are the key factors driving the global hypercholesterolemia drugs market?
• What are the key hypercholesterolemia drugs market trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the vendors in the global hypercholesterolemia drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the hypercholesterolemia drugs market?

Related Reports

• Global Statin Market 2015-2019
• Global Carotid Stent Market 2015-2019
• Global Cardiovascular Implants Market 2015-2019
• Global miRNA Market 2015-2019